Sotorasib

Small molecule

Also known as AMG 510

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
JP
  • KRAS G12C-mutated, unresectable, advanced and/or recurrent NSCLC that has progressed after systemic anticancer therapy
Product first approved 2022amgen.com
EU
  • Lumykras monotherapy for adults with advanced NSCLC with KRAS G12C mutation after at least one prior line of systemic therapy (conditional marketing authorisation)
Product first approved 2022EMA
CA
  • LUMAKRAS® (sotorasib) is indicated for: • the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. This indication is issued market authorization with conditions based on objective response rate (ORR) and duration of response (DOR) (see 14 CLINICAL TRIALS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Product first approved 2021Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Advanced Metastatic Colorectal Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Phase 2 (18)
Colorectal Cancer
NCT07124884 · Federation Francophone de Cancerologie Digestive
2025-08-31 – 2030-12-30 · Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer
What this study did
NCT05845450 · Gruppo Oncologico del Nord-Ovest
2023-05-11 – 2028-05 · Colorectal Cancer, Resectable Colorectal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07543172 · Roswell Park Cancer Institute
2026-10-15 – 2029-06-01 · Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT05398094 · Fundación GECP
2022-03-21 – 2028-12-31 · Non-small Cell Lung Cancer Stage III, KRAS P.G12C
What this study did
NCT04625647 · SWOG Cancer Research Network
2021-04-16 – 2027-12-31 · Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05631249 · Gustave Roussy, Cancer Campus, Grand Paris
2022-12-13 – 2027-12-12 · KRAS P.G12C, Non Small Cell Lung Cancer
What this study did
NCT06582771 · Memorial Sloan Kettering Cancer Center
2024-08-30 – 2027-08 · Non Small Lung Cancer
What this study did
NCT06068153 · ETOP IBCSG Partners Foundation
2025-03 – 2026-12-30 · Metastatic Non Small Cell Lung Cancer, KRAS G12C
What this study did
NCT05815186 · NYU Langone Health
2024-04 – 2026-04 · Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
What this study did
NCT06333678 · Memorial Sloan Kettering Cancer Center
2024-03-20 – 2026-01-27 · Non-Small Cell Lung Cancer
What this study did
NCT04933695 · Amgen
2022-01-28 – 2025-05-28 · Non-small Cell Lung Cancer
What this study did
NCT05311709 · Vestre Viken Hospital Trust
2022-05-30 – 2025-03-01 · Lung Cancer, NSCLC, Stage III, NSCLC Stage IV, Lung Cancer Stage IV, Mutation, Cancer, Cancer, Lung
What this study did
NCT05054725 · Revolution Medicines, Inc.
2021-12-30 – 2024-08-29 · Non-Small Cell Lung Cancer
What this study did
NCT05400577 · Fox Chase Cancer Center
2022-07-13 – 2024-02-01 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07172919 · Amgen
2026-01-02 – 2028-07-01 · Advanced Solid Tumors
What this study did
Phase 1/2 (9)
Non-Small Cell Lung Cancer
NCT07563738 · Orion Corporation, Orion Pharma
2026-03-27 – 2029-09 · Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07012031 · National Cancer Institute (NCI)
2026-06-17 – 2027-06-14 · Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT05074810 · Verastem, Inc.
2022-04-12 – 2027-04 · Non Small Cell Lung Cancer, KRAS Activating Mutation
What this study did
NCT05313009 · Medical University of South Carolina
2022-03-07 – 2023-12-31 · Non-Small Cell Lung Cancer
What this study did
NCT04720976 · Allist Pharmaceuticals, Inc.
2021-03-23 – 2023-12-19 · Solid Tumor, NSCLC
What this study did
NCT05180422 · Criterium, Inc.
2022-06-15 – 2023-01-31 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04092673 · Effector Therapeutics
2019-10-25 – 2025-03-31 · Solid Tumor, Adult
What this study did
NCT05251038 · Devalingam Mahalingam
2022-09-13 – 2023-01-31 · Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
What this study did
Phase 1 (30)
Advanced Metastatic Colorectal Cancer
NCT07318389 · M.D. Anderson Cancer Center
2026-04-22 – 2029-11-14 · Dynamic Tumor Resistance, Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05815173 · NYU Langone Health
2023-08-01 – 2027-08 · Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
What this study did
NCT06333951 · Amgen
2024-09-17 – 2026-11-30 · Thoracic Tumors, Non-small Cell Lung Cancer
What this study did
NCT06249282 · City of Hope Medical Center
2024-04-24 – 2026-11-24 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT04892017 · Deciphera Pharmaceuticals, LLC
2021-06-15 – 2026-03-30 · Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT06127940 · Karolinska University Hospital
2023-10-15 – 2026-01-01 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT05480865 · Navire Pharma Inc., a BridgeBio company
2022-07-06 – 2024-08-22 · Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
What this study did
NCT05374538 · Vitrac Therapeutics, LLC
2022-11-09 – 2023-08-26 · Non-small Cell Lung Cancer
What this study did
NCT04959981 · Erasca, Inc.
2021-09-02 – 2023-04-27 · Advanced Non-squamous Non-small-cell Lung Cancer
What this study did
Other / comorbidity
NCT06892054 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2025-08-08 – 2030-08-08 · Pancreatic Adenocarcinoma
What this study did
NCT06807619 · Memorial Sloan Kettering Cancer Center
2025-01-29 – 2028-01 · Brain Tumor
What this study did
NCT06659341 · Bayer
2024-11-08 – 2027-12-30 · Advanced Solid Tumors Harboring KRAS G12C Mutation
What this study did
NCT04185883 · Amgen
2019-12-17 – 2027-12-05 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
What this study did
NCT06804824 · Vividion Therapeutics, Inc.
2025-02-25 – 2027-08-01 · Advanced Solid Tumors
What this study did
NCT04380753 · Amgen
2020-04-28 – 2026-02-09 · Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
What this study did
NCT06061523 · Amgen
2024-07-15 – 2024-09-09 · Healthy Participants
What this study did
NCT05327491 · Amgen
2022-03-21 – 2022-07-17 · Healthy Participants
What this study did
NCT04887064 · Amgen
2021-04-22 – 2022-03-09 · Hepatic Impairment
What this study did
NCT05048784 · Amgen
2021-08-16 – 2022-02-18 · Healthy Participants
What this study did
NCT05045638 · Amgen
2021-08-20 – 2021-10-10 · Healthy Participants
What this study did
NCT05599828 · Amgen
2020-07-17 – 2020-09-13 · Healthy Participants
What this study did
NCT05571163 · Amgen
2020-03-06 – 2020-06-14 · Healthy Participants
What this study did
NCT05578859 · Amgen
2020-03-11 – 2020-03-24 · Healthy Subjects
What this study did
NCT05581992 · Amgen
2020-01-06 – 2020-01-26 · Healthy Participants
What this study did
NCT05568082 · Amgen
2019-12-03 – 2019-12-17 · Healthy Participants
What this study did
NCT05581758 · Amgen
2019-11-14 – 2019-12-09 · Healthy Participants
What this study did
NCT05577624 · Amgen
2019-11-05 – 2019-12-01 · Healthy Participants
What this study did
NCT05550129 · Amgen
2019-11-13 – 2019-11-25 · Healthy Volunteers
What this study did
NCT05598281 · Amgen
2019-11-05 – 2019-11-19 · Healthy Participants
What this study did
Phase 4 (1)
Other / comorbidity
NCT06314763 · Radboud University Medical Center
2023-11-09 – 2024-03-21 · Drug Drug Interaction Study
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT06497556 · Hoffmann-La Roche
2024-09-23 – 2029-11-30 · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
What this study did
Phase 2 (1)
Other / comorbidity
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT05638295 · National Cancer Institute (NCI)
2024-08-01 – 2028-12-31 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sotorasib: this drugApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(21 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sotorasib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-24 · NCT06249282 · CT.gov ↗
What to watch
December 2026 (2)
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04625647 · CT.gov ↗
What to watch
2027 (11)
May 2027 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-14 · NCT07012031 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT05920356 · CT.gov ↗
What to watch
August 2027 (3)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT05815173 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT06582771 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-08-01 · NCT06804824 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-20 · NCT05118854 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors Harboring KRAS G12C MutationRecruiting
Est. primary completion 2027-11-30 · NCT06659341 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-12 · NCT05631249 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT05398094 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1Brain TumorRecruiting
Est. primary completion 2028-01 · NCT06807619 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Advanced Solid TumorsRecruiting
Est. primary completion 2028-07-01 · NCT07172919 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-09-25 · NCT06252649 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06-01 · NCT07543172 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09 · NCT07563738 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2030-06-30 · NCT07124884 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2030-08-08 · NCT06892054 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 January 2025ApprovalFDA approves LUMAKRAS plus Vectibix for chemorefractory KRAS G12C-mutated mCRC
US, FDA · Source ↗
26 December 2023Complete response letterComplete response letter for full NSCLC approval
US, FDA · Source ↗